ניקסואה מקבלת 15 מיליון דולר מבנק ההשקעות האירופי

גיוס חוב לא מדולל משלים את גיוס ההון של החברה ביוני, ומביא את סך גיוס ההון ל-110 מיליון דולר.

מונט-סן-גיבר, בלגיה – 17 ביוני 2026, GLOBE NEWSWIRE –

Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות רפואיות המתמקדת בפיתוח פתרונות חדשניים לטיפול בדום נשימה חסימתי בשינה (OSA), הודיעה היום כי קיבלה 15 מיליון דולר (13.8 מיליון אירו) בתמורה מהתשלום השני של מסגרת ההלוואה שלה עם הבנק האירופי להשקעות (EIB). משיכת ההלוואה מגיעה לאחר האישור האחרון כי החברה עמדה בקריטריונים שהוגדרו מראש הנדרשים לגישה לתשלום זה.

Nyxoah Receives $15 Million from the European Investment Bank

Non-dilutive debt funding complements the Company’s June equity raise, bringing total capital raised to $110 million

Mont-Saint-Guibert, Belgium – June 17, 2026, GlobeNewswire –

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced that it has received $15 million (€13.8 million) in proceeds from the second tranche of its loan facility with the European Investment Bank (EIB). The drawdown follows the recent confirmation that the Company had satisfied the predefined criteria required to access this tranche.

With this drawdown, Nyxoah has raised approximately $110 million in total new capital in June 2026, combining the proceeds of its underwritten public offering with this non-dilutive EIB financing.

The EIB proceeds are intended first and foremost to accelerate the commercial launch of Genio in the United States, while also supporting continued investment in research and development and the scale-up of manufacturing. As non-dilutive capital, the EIB financing reinforces the Company’s balance sheet without diluting existing shareholders.

“Receiving these funds from the European Investment Bank completes a transformative financing for Nyxoah,” said Olivier Taelman, Chief Executive Officer. “The EIB’s continued support is a strong endorsement of our technology and of the long-term potential of our mission to make sleep simple for OSA patients. This non-dilutive capital, alongside the equity proceeds raised this month, allows us to accelerate the commercial launch of Genio in the United States while continuing to invest in innovation. We are entering the next phase of our growth from a position of strength.”

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Contacts:

Nyxoah

John Landry, CFO

[email protected]

Rémi Renard, Head of Investor Relations & Corporate Communication

[email protected]

Attachment

• ENGLISH_EIB Proceeds ReceivedPR_DRAFT

*** הידיעה מופצת בעולם על ידי חברת התקשורת הבינלאומית GlobeNewswire